The document provides information about hydroxyethyl starch (HES), which is a synthetic colloid used in intravenous fluid therapy to expand plasma volume. HES acts as a plasma expander and is used to treat hypovolemia, but concerns have been raised about its safety profile. The risks of HES include increased risks of kidney injury and bleeding compared to alternative plasma volume expanders like albumin.
The document provides information about hydroxyethyl starch (HES), which is a synthetic colloid used in intravenous fluid therapy to expand plasma volume. HES acts as a plasma expander and is used to treat hypovolemia, but concerns have been raised about its safety profile. The risks of HES include increased risks of kidney injury and bleeding compared to alternative plasma volume expanders like albumin.
The document provides information about hydroxyethyl starch (HES), which is a synthetic colloid used in intravenous fluid therapy to expand plasma volume. HES acts as a plasma expander and is used to treat hypovolemia, but concerns have been raised about its safety profile. The risks of HES include increased risks of kidney injury and bleeding compared to alternative plasma volume expanders like albumin.
The document provides information about hydroxyethyl starch (HES), which is a synthetic colloid used in intravenous fluid therapy to expand plasma volume. HES acts as a plasma expander and is used to treat hypovolemia, but concerns have been raised about its safety profile. The risks of HES include increased risks of kidney injury and bleeding compared to alternative plasma volume expanders like albumin.